Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: Outcome and results of KRAS mutational analysis in plasma

Author: Spindler Karen-Lise G.   Sorensen Morten M.   Pallisgaard Niels   Andersen Rikke F.   Havelund Birgitte M.   Ploen John   Lassen Ulrik   Jakobsen Anders K. M.  

Publisher: Informa Healthcare

ISSN: 0284-186X

Source: Acta Oncologica, Vol.52, Iss.5, 2013-06, pp. : 963-970

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content